Key facts
- Notable investors include Service Provider Capital, Newfund Management, Invariantes Fund, Esplanade Healthtech Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for One Zyme
- ·The full record, as it builds
Funding rounds
No funding rounds for One Zyme are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About One Zyme
Developer of AI-powered research agents designed for pharmaceutical business development. The company offers a platform integrating AI agents that analyze siloed data to provide real-time intelligence on optimal outreach timing, track and identify new opportunities, automate routine research tasks, and generate actionable insights, enabling pharmaceutical and life sciences companies to enhance efficiency and make informed strategic decisions for business growth.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Website
- onezyme.ai/
- Ownership
- Privately Held (backing)
One Zyme doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in One Zyme shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on One Zyme in its N-PORT filings yet. We sweep new filings monthly.